Brazil's health regulator Anvisa authorized on August 20 the start of clinical trials for the country's first messenger RNA (mRNA) vaccine developed entirely at home. The Covid-19 shot was created by Bio-Manguinhos, the immunobiology institute of the Oswaldo Cruz Foundation (Fiocruz), Brazil's leading public biomedical research institution, and is the first product built on fully domestic mRNA technology to reach human testing, according to the agency and the foundation.
The green-lit study is a Phase 1 trial, the first step in humans. It will measure safety and immune response when the vaccine is given as a booster dose to healthy adults aged 18 to 59, at three dose levels: 25, 50 and 100 micrograms. According to the protocol registered on ClinicalTrials.gov under number NCT07640308, the trial is open-label, multicenter, non-randomized and uncontrolled, meaning participants and researchers know which vaccine is being given and there is no comparison group. Each volunteer will be followed for one year. Recruitment is expected to begin in the first quarter of 2027, pending approval by a research ethics committee.
Before reaching this stage, the vaccine went through preclinical testing that Fiocruz says showed protection against the disease, along with toxicology and scale-up studies. What is new for the country lies in the origin of the technology. The news outlet g1 reports that the lipid nanoparticle that shields the RNA and the vaccine's genetic structure were developed in Brazil, without importing or licensing them from foreign laboratories. Fiocruz says its pilot plant is the first in Latin America with Good Manufacturing Practice certification and that it is the first partner in the global mRNA technology transfer program of the World Health Organization (WHO) and the Medicines Patent Pool to bring a product to clinical trials. The project has received R$ 77 million from the Health Ministry, plus funding from the state development bank BNDES and the Pan American Health Organization (PAHO).
It helps to separate what is confirmed from what remains preliminary. Confirmed: the authorization to test, the design of the study, and national mastery of the platform, with a certified pilot plant and public funding. Pending: everything that depends on results, because Phase 1 checks safety and immune response rather than protection against disease, and registration for general use can only be requested once the clinical phases are complete. "The consolidation of this platform expands national capacity to respond to health emergencies, reduces dependence on foreign technologies and creates a basis for the development of new products to address different challenges of the Unified Health System (SUS)", said Fiocruz president Mario Moreira, referring to Brazil's public health system. Anvisa's director-president Leandro Safatle called the study "a concrete demonstration of Brazil's commitment to health protection and to the development of science".
"This is a great milestone for Brazil, so that we can position ourselves as a biotechnology leader in Latin America in this field. It is a milestone for the country's sovereignty and for Brazilian research."
Beyond Covid-19
Those were the words of Patrícia Neves, a Fiocruz researcher who helped develop the vaccine, speaking to g1. Neves, who leads the RNA project at Bio-Manguinhos, summed up the platform's reach: "The potential is enormous. We will have the first Covid-19 vaccine, but we already have studies under way for others, against leishmaniasis and tuberculosis, for example, and we know it is possible to produce therapies for diseases such as cancer", she said in a Fiocruz statement. G1 lists other domestic research lines at an early stage: a cancer vaccine based on tumor antigens, an mRNA treatment that, in animals, made tumor cells produce a protein capable of inducing the tumor's own death, reducing its volume by up to 85%, and a planned mRNA-based version of CAR-T therapy that would remove the need to extract and modify a patient's cells outside the body. All of these remain in laboratories and animal models, with no date for human testing.
What it means for readers
For now, nothing changes. The vaccine does not exist as a product: it is not approved, not for sale and not available through the public system, and it will only reach the market if it passes the remaining clinical phases. Covid-19 boosters on Brazil's national immunization calendar remain the shots already registered with Anvisa. Readers who want to follow the trial or apply as volunteers should wait for Fiocruz's official call, expected in 2027, and rely only on the institution's official channels: participation in clinical research is free of charge, and anyone demanding payment for a spot is running a scam.